Background/Objective: Tedizolid (TZD), an oxazolidinone, causes fewer adverse events than linezolid (LZD). However, studies on the long-term efficacy and safety of TZD, particularly in patients with hematological malignancies (HMs), remain limited. This study aimed to evaluate the safety of long-term TZD use in Japanese patients, including those with HM. Methods: We retrospectively reviewed the medical records of patients aged 15 years and older who received TZD treatment at St. Luke’s International Hospital between 2018 and 2023. Patient demographics, treatment duration, adverse events, and clinical outcomes were analyzed. Results: Data from 35 patients and 40 treatment episodes were analyzed, including 13 episodes in patients with HM, of whom 65.0% were male, with a median age of 69.0 years (IQR: 24.5 years). The median treatment duration was 13.5 days (IQR: 46.8), with a maximum of 203 days. TZD was switched from other anti-MRSA agents in 82.5% of cases, including 42.5% from LZD. One patient discontinued TZD due to liver dysfunction, attributed to concomitant medication use. Clinical cure rates were significantly higher in the non-HM group compared to the HM group (88.9% vs. 38.5%). The 90-day mortality rate differed notably between the HM and non-HM groups (69.2% and 3.7%). Despite 100% microbiological eradication, infection-related mortality rates were 3.7% in the non-HM and 38.5% in the HM group. No reported cases of optic neuritis, Clostridioides difficile colitis, or major bleeding; Conclusions: TZD appears to be safe for long-term use, regardless of HM status, with no major complications observed in this cohort.

Kazuhiro Ishikawa

Yasumasa Tsuda

Nobuyoshi Mori

Antibiotics

Antibiotics (ISSN 2079-6382) is an open access, peer reviewed journal on all aspects of antibiotics. Antibiotics is a multi-disciplinary journal encompassing the general fields of biochemistry, chemistry, genetics, microbiology and pharmacology. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on the length of papers.

Antibiotics is an open access, peer-reviewed journal that focuses on all aspects of antibiotics. This multidisciplinary journal encompasses the fields of biochemistry, chemistry, genetics, microbiology, and pharmacology. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible, and therefore, there is no restriction on the length of papers.

《Antibiotics》是一本开放获取、同行评审的期刊，专注于抗生素的各个方面。该期刊涵盖生物化学、化学、遗传学、微生物学和药理学等多个学科。我们的目标是鼓励科学家尽可能详细地发布他们的实验和理论结果，因此对论文的长度没有限制。

Category	Quartile
医学	2
医学, 药学	2
医学, 传染病学	3

Study on the Efficacy and Safety of Tedizolid in Japanese Patients

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info

Category	Quartile
PHARMACOLOGY & PHARMACY	1